Mog Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MOG (Myelin Oligodendrocyte Glycoprotein) is a type I transmembrane glycoprotein that is a minor but immunologically significant component of the central nervous system (CNS) myelin sheath. Despite comprising only 0.1-0.5% of total myelin protein, MOG is a major target of autoimmune responses in multiple sclerosis and related demyelinating diseases. [1]
| Attribute | Value | [2]
|-----------|-------| [3]
| Protein Name | Myelin Oligodendrocyte Glycoprotein | [4]
| Gene | MOG |
| UniProt ID | P20916 |
| PDB Structure | 1PKV, 3DUU, 5E9R |
| Molecular Weight | 26-28 kDa (core protein) + glycosylation |
| Subcellular Localization | Plasma membrane, myelin sheath (outer surface) |
| Protein Family | Immunoglobulin superfamily (Ig-like V-type) |
MOG is a transmembrane protein with a distinct domain organization:
Key structural features:
MOG performs several important functions in CNS myelin:
A distinct autoimmune disorder characterized by:
Key features distinguishing MOGAD from MS:
The study of Mog Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Breithaupt C, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. J Neurochem. 2008. ↩︎
Reindl M, et al. MOG antibodies in disease: a systematic review and combined analysis. Neurology. 2020. ↩︎
Hohlfeld R, et al. The role of MOG in multiple sclerosis and experimental autoimmune encephalomyelitis. Lancet Neurol. 2021. ↩︎
Jurynczyk M, et al. MOG antibody disease: clinical phenotype, treatment and outcomes. J Neurol Neurosurg Psychiatry. 2021. ↩︎